Dish of the day
No Joiners Today
Off the menu
No Leavers Today
Whats cooking in the IPO kitchen?
The pantry is bare!
Mereo BioPharma 22p £27.4m (AIM:MPH)
Private placement completed raising $70.0 million (£56.0 million) before expenses. Price per Placing Share of 17.4 pence.
Mereo is also announcing today plans to advance etigilimab (Anti-TIGIT) into a Phase 1b study in Q4 2020 alongside progressing its rare disease product portfolio. This is based on the Company's existing promising clinical data with etigilimab as well as the increasing interest in TIGIT as an immuno-oncology target. The Company intends to complete a strategic partnership for setrusumab for the treatment of osteogenesis imperfecta ("OI") prior to initiation of the pivotal Phase 3 study and to complete the ongoing Phase 2 study of alvelestat for the treatment of alpha-1 antitrypsin deficiency ("AATD"), with topline data currently expected in 2H 2021.
DeepMatter Group 2.05p £15.1m (AIM:DMTR)
The company focusing on digitising chemistry, today announces plans to interface its DigitalGlassware platform with the Waters UNIFI Scientific Information System to create comprehensive, universally accessible, easily-understandable insights for chemists.
Following the integration, scheduled to be completed later in the year and which will use the UNIFI Application Programming Interface (API), UNIFI customers will be able to view and analyse chemistry analytical data from their experiments via the DigitalGlassware web portal, making their data more easily accessible and shareable.
Blackbird 17.5p £58.7m (AIM:BIRD)
The developer and seller of the market-leading Blackbird cloud video editing platform, announced today that Whisper, the sports and live event production specialist, has chosen Blackbird to drive major video production efficiencies for its clients, including Formula One.
Co-founded by David Coulthard, Jake Humphrey and Sunil Patel, Whisper is a leading broadcast production company. Whisper specializes in the production of entertainment and sports content with a portfolio that includes Formula One, the Rugby World Cup, the Women's Six Nations, the Paralympics, W Series racing, the NFL and SailGP.
Hutchison China MediTech 355p £2.46bn (AIM:HCM)
The Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review. Based on the preset criteria, the IDMC recommended that the trial continue. FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal junction ("GEJ") adenocarcinoma who have progressed after first-line standard chemotherapy.
Avacta 140.75p £291m (AIM:AVCT)
The developer of Affimer® biotherapeutics and reagents, announces in response to substantial institutional interest, its intention to raise gross proceeds of up to £45 million by means of a placing to institutional and other investors, a direct subscription with the Company and offers to retail and other investors via the PrimaryBid platform, of up to 37,500,000 shares, in each case at a price of 120 pence per share.
The Issue Price is at a discount of approximately 4.4 per cent to the 30 day volume weighted average price of the Ordinary Shares on AIM on 3 June 2020, being 125.3 pence per Ordinary Share.
Proceeds to fund the rapid scale-up of the broader Affimer® diagnostic products opportunities including COVID-19 antigen rapid testing and accelerated expansion of the in-house Affimer® and pre|CISION cancer therapy pipeline.
Strategic Minerals 0.465p £6.8m (AIM:SML)
£1.1m raised at 0.45p, primarily to settle the final payment on Redmoor purchase.
Existing shareholders provided an opportunity to participate on the same basis as the placing. The proceeds of the Placing will be chiefly used for payment of the remaining balance of consideration of £990,000 due to New Age Exploration Limited for the sale of its interest in Cornwall Resources Limited ("CRL"), the holder of the Redmoor Tin/Tungsten Project.
"The Company continues to limit equity raisings to only fund projects it believes will value add over time. Today's raise not only achieves this, through securing the balance of the Redmoor acquisition, but the Board considers that it will also remove a perceived market overhang associated with the need to fund this liability.
The Board is especially pleased that, after repeated requests from shareholders to be involved with equity raises, it has been able to identify an efficient, cost effective method of allowing shareholders access to an issue."
Open Orphan 14.4p £85.4m (AIM:ORPH)
Launch of hVIVO COVID Clear Test, the Company's antibody testing service, following the successful completion of installation, testing and training.
The antibody tests, which utilise the Quotient MosaiQ system and MosaiQ COVID-19 Antibody Microarray, offer best in class COVID-19 antibody testing performance and will require a full blood draw. hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals. Samples will be tested in the Company's London laboratory with results returned within 48 hours.
HY Mar 20 results. H1 business highlights
· Business resilience and exceptional staff and client engagement since COVID-19 restrictions imposed
· £1.8 billion of net inflows in six months, the highest level on record (H1 2019: £887 million)
· AUM of £14.4 billion Read More – Source